Abstract
We have evaluated the feasibility of the use of neoadjuvant imatinib mesylate in the management of unresectable localized gastrointestinal stromal tumors. In a pilot experience, two patients with unresectable gastrointestinal tumors were treated with neoadjuvant imatinib. Their treatment course and surgical outcomes are described. In both cases, the patient attained sufficient tumor regression to enable complete resection of tumor. We conclude that in the management of unresectable gastrointestinal stromal tumors, neoadjuvant administration of imatinib may facilitate sufficient tumor regression to facilitate subsequent tumor resection with curative intent.
Publication types
-
Case Reports
-
Evaluation Study
MeSH terms
-
Benzamides
-
Biopsy
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Drug Administration Schedule
-
Follow-Up Studies
-
Gastrectomy
-
Gastrointestinal Neoplasms / diagnosis
-
Gastrointestinal Neoplasms / drug therapy*
-
Gastrointestinal Neoplasms / pathology
-
Humans
-
Imatinib Mesylate
-
Intestinal Polyps / diagnosis
-
Intestinal Polyps / pathology
-
Israel
-
Male
-
Middle Aged
-
Neoadjuvant Therapy / methods*
-
Neoplasm Invasiveness / diagnostic imaging
-
Piperazines / administration & dosage
-
Piperazines / therapeutic use*
-
Postoperative Period
-
Pyrimidines / administration & dosage
-
Pyrimidines / therapeutic use*
-
Remission Induction / methods
-
Splenectomy
-
Stromal Cells / drug effects*
-
Stromal Cells / pathology
-
Tomography, Spiral Computed
-
Treatment Outcome
Substances
-
Benzamides
-
Piperazines
-
Pyrimidines
-
Imatinib Mesylate